Zai Lab Earnings Call: Key Takeaways
Zai Lab is pivoting toward a global oncology player with Zozi's 81.8% ORR in small cell lung cancer and a $250 million capital raise.
- Call
- Nov 5, 2026, 8:00 AM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Filing type
Alerts
Time
636 alerts with these filters
Zai Lab is pivoting toward a global oncology player with Zozi's 81.8% ORR in small cell lung cancer and a $250 million capital raise.
Tronox emphasizes its vertical integration and proprietary mining techniques as key competitive advantages in the global titanium dioxide market.
1-800-FLOWERS is undergoing a strategic transformation, divesting non-core assets like PersonalizationMall to focus on primary websites where demand declines are moderating toward low single digits.
Acacia Research delivered $54.4 million in revenue, leveraging its diversified model with strong energy performance at Benchmark and public security gains, while managing operational restructuring at Deflecto amid soft housing market conditions.
Intensity Therapeutics is restarting Phase 3 and Phase 2 trials after funding-related pauses, but remains severely capital-constrained with only $8.5 million in cash, making future enrollment timelines entirely dependent on successful capital raises.
Novelis delivered 20% EBITDA growth despite operational headwinds, focusing on the Bay Minette commissioning and aggressive cost-cutting to offset $78 million in tariff impacts and labor strikes.
VEECO delivered solid Q3 results with $209M revenue, driven by AI infrastructure demand, while forecasting significant 2027 acceleration and navigating supply chain constraints and a pending merger with Excelitas.
Personalis presented interim Victory study data for NeXT Personal, demonstrating 96% pre-surgical sensitivity and 100% detection of colorectal cancer recurrences with significant lead-time advantages.
MercadoLibre is prioritizing ecosystem engagement and market share over short-term margins, leveraging high-growth credit and advertising segments to fund aggressive logistics and AI investments.
Franklin Covey delivered fiscal 2026 results within guidance, pivoting to a high-leverage subscription model with strong North American deferred revenue growth of 17% setting a foundation for fiscal 2027 acceleration.
CAVA delivered 22.1% revenue growth and reached 500 restaurants, though margins faced pressure from labor investments and third-party delivery mix despite positive traffic and strong new unit productivity.
STAAR Surgical delivered record nine-month revenue driven by a structural shift from lasers to lenses, though supply constraints in China and temporary margin pressures from ERP implementation impacted the quarter.
Caris Life Sciences delivered record Q3 2026 revenue of $275.4M, up 27%, while raising full-year guidance and expanding its oncology platform into monitoring and MRD markets.
Figma delivered a strong Q3 beat with 43% revenue growth, driven by AI monetization and high net dollar retention, while aggressively investing in first-party models and its 'full stack canvas' strategy.
TKO delivered a strong beat-and-raise quarter driven by record UFC performance and accelerating WWE partnership revenue despite event timing headwinds.
Joby Aviation is transitioning from development to early operations, leveraging a strong $2.2 billion balance sheet and the strategic acquisition of Resonance Sciences to scale defense and autonomy.
Veracyte delivered a Q3 revenue beat but significantly lowered Decipher prostate volume expectations, signaling a transition from outsized guideline-driven growth to a normalized, more competitive market environment.
Alto Ingredients delivered its fifth consecutive quarter of positive EBITDA, driven by healthy crush margins and 45Z tax credits, while pivoting sales to domestic markets to optimize economics over lower-margin European exports.
Sezzle delivered a strong Q3 with 42.6% revenue growth and significant margin expansion, driven by AI-led operational efficiencies and a successful shift toward a subscription-based 'Costco' model.
Lumen is pivoting from legacy copper to a digital-first platform, leveraging AI-driven demand and $13.5 billion in PCF deals to drive strategic revenue growth despite overall revenue declines.
Allegiant expanded margins despite high fuel costs, leveraging a flexible capacity model and Sun Country integration to maintain full-year EPS guidance of over $6.
Ascent Industries delivered strong Q3 2026 results with 37.8% revenue growth and significant EBITDA margin expansion, though management cautioned about seasonal Q4 margin compression.
Paycom delivered a strong Q3 2026 with 10% revenue growth and significant margin expansion driven by automation and AI-led operational efficiencies.
Nuvation Bio reported strong Iptrosi growth despite a 15% market-wide decline in ROS1 TKI starts, while advancing its IDH1 mutant glioma program toward 2027 data readouts.
DHI Group shows a tale of two segments: ClearanceJobs is thriving with 18% revenue growth, while Dice faces continued enterprise renewal pressure despite narrowing booking declines.
Acadia delivered strong Q3 results with 22% revenue growth, raised DAYBUE guidance, and optimized its Phase 3 ADP program despite a Phase 2 primary endpoint miss, supported by a $976 million cash position.
Energy Recovery is pivoting to a pure-play water company with a record $525 million pipeline and rebounding Middle East mega-projects, though management remains evasive on specific shipment timing and near-term guidance.
e.l.f. Beauty delivered exceptional Q2 results with 51% revenue growth, raising FY27 guidance behind strong momentum in international markets and the record-breaking Road acquisition performance.
TrueBlue delivered a strong Q3 beat driven by 100% growth in energy sector revenue and significant operating leverage, leading to a robust Q4 revenue growth outlook of 20% to 24%.
Purple Innovation faces significant wholesale headwinds and manufacturing deleverage, prompting a guidance cut for EBITDA despite positive operating cash flow and upcoming product refreshes.